ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET
Company Participants
Al Kildani - Senior Vice President, Investor Relations and Corporate Communications
Steve Davis - President and Chief Executive Officer
Brendan Teehan - Executive Vice President, Chief Operating Officer, Head of Commercial
Doug Williamson - Executive Vice President, Head of Research and Development
Mark Schneyer - Executive Vice President, Chief Financial Officer
Parag Meswani - Senior Vice President, Trofinetide, Rare Disease Franchise
Conference Call Participants
Tessa Romero - JPMorgan
Ashwani Verma - UBS
David Hoang - Citigroup
Charles Duncan - Cantor Fitzgerald
Ritu Baral - TD Cowen
Jeffrey Hung - Morgan Stanley
Gregory Renza - RBC Capital Markets
Ami Fadia - Needham
Uy Ear - Mizuho
Joel Beatty - Baird
Marc Goodman - Leerink Partners
Yatin Suneja - Guggenheim
Operator
Good day ladies and gentlemen and welcome to ACADIA Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. My name is Abigail and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. [Operator Instructions]
I would now like to turn the presentation over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please proceed.
Al Kildani
Good afternoon and thank you for joining us on today's call to discuss ACADIA’s fourth quarter and full year 2023 earnings results. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial, who will discuss our strong commercial franchises, DAYBUE and NUPLAZID.
Doug Williamson, our Head of Research and Development will provide an update on our pipeline programs; and Mark Schneyer, our Chief Financial Officer will review the financial highlights. Steve will then provide some closing thoughts before we open up the call to your questions. In addition, Parag Meswani, Senior Vice President: Trofinetide, Rare Disease Franchise, will be available for the Q&A session. We are using supplemental slides which are available on our website's Events and Presentations section.
Before proceeding, I would like to remind you that during our call today we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements including goals, expectations, plans, prospects, growth potential, timing of events or future results are based on current information, assumptions, and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements which are made only as of today's date.